Search Results - Ligong Lu

Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma by Lei Jiang, Luan Li, Yongzhuang Liu, Meixiao Zhan, Ligong Lu, Shengtao Yuan, Yanyan Liu

Connect to this object online.

Hypoxia-degradable and long-circulating zwitterionic phosphorylcholine-based nanogel for enhanced tumor drug delivery by Shaojun Peng, Boshu Ouyang, Yongjie Xin, Wei Zhao, Shun Shen, Meixiao Zhan, Ligong Lu

Connect to this object online.

Review immune response of targeting CD39 in cancer by Yao Liu, Zhongliang Li, Xiaoguang Zhao, Jing Xiao, Jiacheng Bi, Xian-Yang Li, Guokai Chen, Ligong Lu

Connect to this object online.

Temporary vaccination clinic for COVID-19 in Zhuhai, China by Hao Jin, Jing Chu, Wei Zhao, Qiao Ye, Meixiao Zhan, Xiaoling Han, Ligong Lu, Junwei Liu, Zhaohui Li, Min Cui

Connect to this object online.

Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China by Zhiqiang Wang, Zhibo Zhang, Yong Li, Li Sun, Dezhen Peng, Danyu Du, Xian Zhang, Luwei Han, Liwen Zhao, Ligong Lu, Hongzhi Du, Shengtao Yuan, Meixiao Zhan

Connect to this object online.

Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway by Xiaoying Hou, Hongzhi Du, Xingping Quan, Lei Shi, Qianqian Zhang, Yao Wu, Yang Liu, Jing Xiao, Yong Li, Ligong Lu, Xun Ai, Meixiao Zhan, Shengtao Yuan, Li Sun

Connect to this object online.